Updated: Jul 14, 2020
On June 20th, the 2020 Sino-American Pharmaceutical Professionals Association (SAPA)’s Investment Summit and Roadshow was held to huge success, gathering many venture capitalist investors and exciting early-stage healthcare firms.
It quickly became clear that one standout company stole the show: Clerio Vision, a company focused on vision correction. Clerio delivered a convincing presentation on their cutting-edge vision correction technology, Laser Induced Refractive Index Correction (LIRIC) and won the first prize in the summit. Based on its 2018 Nobel Prize winning technology and experts with years knowledge on femtosecond laser R&D, LIRIC can improve conventional products across three multi-billion-dollar vision correction markets: cornea, contacts, and IOLs.
“LIRIC is based on a unique laser platform that changes the refractive index to correct vision. We have conducted the world’s first human clinical trial for non-invasive vision correction in cornea successfully.” Alex Zapesochny, the CEO of Clerio Vision said, “current LASIK permanently thins out the cornea, making it a one-time procedure and the potential complications from LASIK are tied to tissue healing issues.” As Clerio Vision’s investor, Bridge Point Capital believes that LIRIC has the potential to become a real game changer in the vision correction area.
SAPA was established in 1993 and was formed by combining promising biotech firms with investors from both China and the US to seek bilateral opportunities. Since its inception, SAPA rapidly became one of the most active Chinese professional associations in the US with five chapters and more than 6,000 members. SAPA’s members are primarily from large and mid-sized pharmaceutical and biotech companies in the US, with areas of expertise covering almost every aspect of pharmaceutical research and development as well as production. The organization’s large membership base and their superb scientific and technical abilities has allowed SAPA to be a key source for knowledge exchange on the latest developments in the pharmaceutical, biotechnology, and generic drug industries.
About Bridge Point Capital:
Bridge Point Capital is a private equity firm based in New York focusing on investment in cross-border healthcare. We are dedicated to discovering and supporting healthcare and life science companies that possess revolutionary technologies that promote human health. By leveraging our team’s experience in and understanding of capital markets and medical industry, we discover and advise the most excellent teams and enterprises, seeking to build a platform that advance the interests of both healthcare companies and investors.